Skip to main
STRO
STRO logo

STRO Stock Forecast & Price Target

STRO Analyst Ratings

Based on 13 analyst ratings
Buy
Strong Buy 46%
Buy 23%
Hold 23%
Sell 8%
Strong Sell 0%

Bulls say

Sutro Biopharma Inc. is showing a positive outlook due to promising preclinical data for its drug candidates, particularly STRO-004, which demonstrated significant improvements in safety and anti-tumor activity compared to existing therapies. The company's strategic decision to reduce its workforce by approximately 50% aims to streamline operations and is expected to lead to a substantial decrease in operating expenses, projected to decline by 50-70% starting in the second quarter of 2025. Additionally, the ongoing development of innovative products such as STRO-006, which possesses enhanced safety and efficacy characteristics, positions the company favorably in a competitive market, highlighting its commitment to advancing its biopharmaceutical pipeline.

Bears say

Sutro Biopharma faces significant risks that could impair its financial performance, particularly if the clinical results for its lead antibody-drug conjugate candidates fall short of expectations, leading to decreased market penetration and elongated approval timelines. The fiscal year 2024 registered a net loss of $227.4 million, corresponding to a loss of $2.96 per share, while cash reserves decreased to $316.9 million from $388.3 million within three months, indicating potential liquidity concerns. Additionally, management's decision to implement a nearly 50% reduction in workforce and discontinue its lead luvelta program reflects a strategic retreat that may negatively impact future growth prospects and investor confidence.

STRO has been analyzed by 13 analysts, with a consensus rating of Buy. 46% of analysts recommend a Strong Buy, 23% recommend Buy, 23% suggest Holding, 8% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Sutro Biopharma Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Sutro Biopharma Inc (STRO) Forecast

Analysts have given STRO a Buy based on their latest research and market trends.

According to 13 analysts, STRO has a Buy consensus rating as of Sep 9, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $12.14, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $12.14, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Sutro Biopharma Inc (STRO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.